[Results] 4 weeks on 15mg, full numbers, ask me anything boring
Here it is: 4 weeks on 15mg, full numbers, ask me anything boring. One person, one log, no control group, so read it accordingly.
4 weeks and 15mg — those are the numbers, and they are the ones I am willing to defend.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Agreed, and the framing that helps is: this is a phase 2 compound with phase 3 running. Everything else is inference.
nothing here is available as a prescription product, so read every thread with that in mind
Sent a vial to Medutest out of curiosity. Result was 99.6% against a claimed 99.0%, which is the first independent number I had seen for this compound anywhere.
a lot of the confident posting here is extrapolation
not approved anywhere, which is the single most important fact in this board
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Correction: TRIUMPH is the phase 3 programme.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
the escalation is where most of the reported trouble sits
What do you think the glucagon component is adding, specifically?
It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.
the glucagon component is why the metabolic story reads differently
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
The early fullness profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
Yes — the comparison threads are apples to oranges and they generate more heat than anything else here.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
How fast was the escalation? That is usually the variable that explains the reports.
phase 2 data only, and people quote it like it is a label
- 1It is a triple agonist at the GLP-1, GIP and glucagon receptors. The…12 comments in this branch · started by u/vito_beaulieu
- 2Agreed, and the framing that helps is: this is a phase 2 compound with phase…8 comments in this branch · started by u/honest_syringe_2025